Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Dig Surg. 2021;38(3):198-204. doi: 10.1159/000509170. Epub 2021 Mar 26.
Additional surgery is necessary in cases with non-curative endoscopic submucosal dissection. It is still unknown whether preceding endoscopic submucosal dissection (ESD) for T1 colorectal carcinoma affects the short outcomes of patients who underwent additional surgery or not as compared with surgery alone without ESD.
Patients (101 pairs) with T1 colorectal cancer who underwent additional laparoscopic-assisted surgery after endoscopic submucosal dissection (additional surgery group, n = 101) or laparoscopic-assisted surgery alone (surgery alone group, n = 101) were matched (1:1). Short-term morbidity, operation outcomes, and lymph node metastasis of the resected specimen were compared.
There were no significant differences between the additional laparoscopic-assisted surgery and laparoscopic-assisted surgery alone groups in lymph node metastasis (9.9 vs. 5.9%, respectively, p = 0.297), operative time (147.76 ± 52.00 min vs. 156.50 ± 54.28 min, p = 0.205), first flatus time (3.56 ± 1.10 days vs. 3.63 ± 1.05 days, p = 0.282), first stool time (4.30 ± 1.04 days vs. 4.39 ± 1.22 days, p = 0.293), time to intake (5.00 ± 1.18 days vs. 5.25 ± 1.39 days, p = 0.079), blood loss (44.75 ± 45.40 mL vs. 60.40 ± 78.98 mL, p = 0.603), harvest lymph nodes (18.74 ± 7.22 vs. 20.32 ± 9.69, p = 0.438), postoperative surgical complications (p = 0.733), and postoperative length of hospital stay (8.68 ± 4.00 days vs. 8.39 ± 1.94 days, p = 0.401).
ESD did not increase the difficulty of additional laparoscopic-assisted surgery, hospital stay, or the incidence of postoperative complications. Additional laparoscopic-assisted surgery is safe and recommended for patients with T1 cancer at high risk of lymph node metastasis and residual cancer after non-curative ESD.
内镜黏膜下剥离术(ESD)非治愈性切除的病例需要追加外科手术。对于 T1 结直肠癌患者,与单纯外科手术相比,先行 ESD 是否会影响追加外科手术后患者的短期结局,目前尚不清楚。
对 101 例行内镜黏膜下剥离术(ESD)后行腹腔镜辅助追加手术(追加手术组,n = 101)或单纯腹腔镜辅助手术(单纯手术组,n = 101)的 T1 结直肠癌患者进行了 1:1 配对。比较两组的短期发病率、手术结果和切除标本的淋巴结转移情况。
追加腹腔镜辅助手术组与单纯腹腔镜辅助手术组在淋巴结转移方面无显著差异(分别为 9.9%和 5.9%,p = 0.297),手术时间(147.76 ± 52.00 分钟 vs. 156.50 ± 54.28 分钟,p = 0.205)、首次排气时间(3.56 ± 1.10 天 vs. 3.63 ± 1.05 天,p = 0.282)、首次排便时间(4.30 ± 1.04 天 vs. 4.39 ± 1.22 天,p = 0.293)、开始进食时间(5.00 ± 1.18 天 vs. 5.25 ± 1.39 天,p = 0.079)、出血量(44.75 ± 45.40 毫升 vs. 60.40 ± 78.98 毫升,p = 0.603)、淋巴结清扫数(18.74 ± 7.22 个 vs. 20.32 ± 9.69 个,p = 0.438)、术后手术并发症(p = 0.733)和术后住院时间(8.68 ± 4.00 天 vs. 8.39 ± 1.94 天,p = 0.401)。
ESD 并未增加追加腹腔镜辅助手术的难度、住院时间或术后并发症的发生率。对于非治愈性 ESD 后淋巴结转移和残留癌症风险较高的 T1 癌症患者,追加腹腔镜辅助手术是安全的,推荐使用。